REGN

Regeneron Pharmaceuticals

Health Care

Biotechnology

Tarrytown, New York

Balance Sheet 31 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets - CashAndCashEquivalents	$2.5B	$2.7B	$3.1B	$2.9B	$2.2B
Assets - MarketableSecuritiesCurrent	$6.5B	$8.1B	$4.6B	$2.8B	$1.4B
Assets - AccountsReceivable	$6.2B	$5.7B	$5.3B	$6.0B	$4.1B
Assets - Inventories	$3.1B	$2.6B	$2.4B	$2.0B	$1.9B
Assets - PrepaidExpensesAndOtherCurrentAssets	$349.2M	$386.6M	$411.2M	$332.4M	$160.8M
Assets - TotalCurrentAssets	$18.7B	$19.5B	$15.9B	$14.0B	$9.8B
Assets - Property,PlantAndEquipment	$4.6B	$4.1B	$3.8B	$3.5B	$3.2B
Assets - MarketableSecuritiesNoncurrent	$8.9B	$5.4B	$6.6B	$6.8B	$3.1B
Assets - DeferredTaxAssets	$3.3B	$2.6B	$1.7B	$876.9M	$761.5M
Assets - FinanceLeaseAssets	$591.2M	$605.7M	$620.3M	$631.3M	$645.7M
Assets - OtherNoncurrentAssets	$1.1B	$444.1M	$336.4M	$216.1M	$168.1M
Assets - TotalAssets	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B
Liabilities - AccountsPayable	$789.5M	$606.6M	$589.2M	$564.0M	$475.5M
Liabilities - AccruedLiabilities	$571.1M	$655.0M	$648.3M	$383.9M	$435.9M
Liabilities - ContractLiabilitiesCurrent	$627.7M	$458.9M	$477.9M	$442.0M	$577.7M
Liabilities - OtherCurrentLiabilities	$213.2M	$11.7M	$300.0K	$326.3M	$122.4M
Liabilities - TotalCurrentLiabilities	$3.9B	$3.4B	$3.1B	$3.9B	$2.7B
Liabilities - LongTermDebt	$2.0B	$2.0B	$2.0B	$2.0B	$2.0B
Liabilities - FinanceLeaseLiabilitiesNoncurrent	$720.0M	$720.0M	$720.0M	$0	$717.2M
Liabilities - DeferredTaxLiabilitiesNoncurrent	$93.0M	$50.4M	$58.2M	$123.5M	$100.5M
Liabilities - OtherNoncurrentLiabilities	$1.6B	$854.1M	$638.0M	$680.2M	$687.1M
Liabilities - TotalLiabilities	$8.4B	$7.1B	$6.6B	$6.7B	$6.1B
Equity - PreferredStock	$0	$0	$0	$0	$0
Equity - AdditionalPaidInCapital	$12.9B	$11.4B	$9.9B	$8.1B	$6.7B
Equity - RetainedEarnings(deficit)	$31.7B	$27.3B	$23.3B	$19.0B	$10.9B
Equity - AccumulatedOtherComprehensiveIncome(loss)	$-7.9M	$-80.9M	$-238.8M	$-26.2M	$29.3M
Equity - TotalStockholdersEquity	$29.4B	$26.0B	$22.7B	$18.8B	$11.0B
Equity - TotalLiabilitiesAndStockholdersEquity	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B
Equity - TotalLiabilitiesandEquity	$37.8B	$33.1B	$29.2B	$25.4B	$17.2B
Validation - L+E Components Sum Difference	$0	$0	$0	$0	$0

Income Statement 19 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
IncomeStatement - Revenues - NetRevenues/ProductSales	$14.2B	$13.1B	$12.2B	$16.1B	$8.5B
IncomeStatement - CostsAndExpenses - ResearchAndDevelopmentExpense	$5.1B	$4.4B	$3.6B	$2.9B	$2.6B
IncomeStatement - CostsAndExpenses - Selling,GeneralAndAdministrative	$3.0B	$2.6B	$2.1B	$1.8B	$1.3B
IncomeStatement - OtherIncomeExpense - OperatingIncome(loss)	$4.0B	$4.0B	$4.7B	$8.9B	$3.6B
IncomeStatement - OtherIncomeExpense - InterestExpense	$46.1M	$73.0M	$59.4M	$57.3M	$56.9M
IncomeStatement - OtherIncomeExpense - InterestIncome	$711.4M	$495.9M	$160.1M	$45.8M	$75.4M
IncomeStatement - OtherIncomeExpense - Gain(loss)OnInvestments/securities	$117.7M	$-237.8M	$-39.8M	$386.1M	$196.0M
IncomeStatement - OtherIncomeExpense - OtherNonoperatingIncome(expense)	$844.4M	$225.2M	$179.3M	$436.3M	$290.7M
IncomeStatement - OtherIncomeExpense - Income(loss)BeforeIncomeTaxes	$4.8B	$4.2B	$4.9B	$9.3B	$3.8B
IncomeStatement - IncomeTax - IncomeTaxExpense(benefit)	$367.3M	$245.7M	$520.4M	$1.3B	$297.2M
IncomeStatement - IncomeTax - EffectiveTaxRate	$0	$0	$0	$0	$0
IncomeStatement - NetIncomeAndEps - NetIncome(loss)	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B
IncomeStatement - NetIncomeAndEps - NetIncome(loss)AttributableToCompany	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B
IncomeStatement - NetIncomeAndEps - BasicEarningsPerShare	$41	$37	$41	$76	$33
IncomeStatement - NetIncomeAndEps - DilutedEarningsPerShare	$38	$35	$38	$72	$31
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingBasic	$107.9M	$106.7M	$107.1M	$105.7M	$107.6M
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingDiluted	$115.1M	$113.7M	$113.5M	$112.2M	$115.1M
IncomeStatement - NetIncomeAndEps - ComprehensiveIncome(loss)	$4.5B	$4.1B	$4.1B	$8.0B	$3.5B

Cash Flow Statement 18 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
CashFlow - OperatingActivities - NetIncome	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B
CashFlow - OperatingActivities - DepreciationAndAmortization	$482.9M	$421.0M	$341.4M	$286.2M	$235.9M
CashFlow - OperatingActivities - ShareBasedCompensation	$982.8M	$885.0M	$725.0M	$601.7M	$432.0M
CashFlow - OperatingActivities - DeferredIncomeTaxes	$-757.3M	$-837.8M	$-746.4M	$-147.1M	$75.6M
CashFlow - OperatingActivities - ChangesInOperatingAssetsAndLiabilities	$1.8B	$768.5M	$169.7M	$2.5B	$1.9B
CashFlow - OperatingActivities - NetCashFromOperatingActivities	$4.4B	$4.6B	$5.0B	$7.1B	$2.6B
CashFlow - InvestingActivities - CapitalExpenditures(pp&e)	$755.9M	$718.6M	$590.1M	$551.9M	$614.6M
CashFlow - InvestingActivities - PurchasesOfMarketableSecurities/investments	$16.6B	$11.6B	$7.5B	$7.0B	$3.2B
CashFlow - InvestingActivities - ProceedsFromSales/maturitiesOfMarketableSecurities/investments	$15.0B	$9.4B	$5.6B	$2.2B	$3.8B
CashFlow - InvestingActivities - NetCashFromInvestingActivities	$-2.5B	$-3.2B	$-3.8B	$-5.4B	$-70.6M
CashFlow - FinancingActivities - PaymentsForRepurchaseOfCommonStock	$2.6B	$2.2B	$2.1B	$1.6B	$5.8B
CashFlow - FinancingActivities - ProceedsFromIssuanceOfCommonStock	$1.5B	$1.1B	$1.5B	$1.7B	$2.6B
CashFlow - FinancingActivities - PaymentsRelatedToTaxWithholdingForShareBasedCompensation	$1.0B	$700.6M	$445.7M	$1.0B	$680.8M
CashFlow - FinancingActivities - NetCashFromFinancingActivities	$-2.2B	$-1.8B	$-1.0B	$-1.0B	$-2.0B
CashFlow - CashReconciliationAndSupplemental - NetChangeInCash	$-248.8M	$-381.6M	$221.3M	$690.8M	$577.0M
CashFlow - CashReconciliationAndSupplemental - IncomeTaxesPaid	$743.0M	$870.3M	$1.5B	$1.2B	$188.1M
CashFlow - CashReconciliationAndSupplemental - InterestPaid	$52.6M	$73.1M	$53.7M	$55.8M	$23.2M

Regeneron Pharmaceuticals

Balance Sheet 31 Accounts • 5 Years

Income Statement 19 Accounts • 5 Years

Cash Flow Statement 18 Accounts • 5 Years

Stock Market Data (1 Year) Live Yahoo Finance Data

Recent Price History